TABLE 2.
Cross-tabulation of variables of interest by percentage of measures in the therapeutic rangea
| Variable | Category or measure | Value corresponding to proportion of vancomycin measures in therapeutic range |
P value | ||
|---|---|---|---|---|---|
| <50% (n = 63) | ≥50% (n = 14) | Total (n = 77) | |||
| Gender [no. (%)] | Female | 21 (33) | 8 (57) | 29 (38) | 0.10 |
| Male | 42 (67) | 6 (43) | 48 (62) | ||
| ECMO system [no. (%)] | VA | 39 (62) | 6 (43) | 45 (58) | 0.21 |
| VV | 21 (33) | 8 (57) | 29 (38) | ||
| Other | 3 (5) | 0 (0) | 3 (4) | ||
| Diagnosis [no. (%)] | Cardiac | 36 (57) | 6 (43) | 42 (55) | 0.62 |
| Respiratory | 20 (32) | 6 (43) | 26 (34) | ||
| Other/sepsis | 7 (11) | 2 (14) | 9 (12) | ||
| Mortality [no. (%)] | No | 36 (57) | 12 (86) | 48 (62) | 0.05 |
| Yes | 27 (43) | 2 (14) | 29 (38) | ||
| Renal replacement therapy [no. (%)] | No | 24 (39) | 9 (64) | 33 (43) | 0.08 |
| Yes | 38 (61) | 5 (36) | 43 (57) | ||
| Age (years) | Mean (SD) | 44 (16) | 39 (18) | 43 (17) | 0.33 |
| Weight (kg) | Mean (SD) | 80 (70–90) | 79 (69–80) | 80 (70–88) | 0.58 |
| APACHE III score | Mean (SD) | 88 (36) | 81 (26) | 87 (35) | 0.50 |
| Total ECMO duration (days) | Median (IQR) | 7 (4–17) | 9 (6–16) | 8 (5–16) | 0.34 |
| ICU length of stay (days) | Median (IQR) | 23 (9–39) | 32 (20–42) | 25 (11–39) | 0.30 |
| Hospital length of stay (days) | Median (IQR) | 34 (13–58) | 41 (20–63) | 35 (14–59) | 0.30 |
| No. of vancomycin doses | Median (IQR) | 7 (2–12) | 9 (4–11) | 7 (2–12) | 0.57 |
| No. of vancomycin measurements | Median (IQR) | 6 (2–9) | 4 (2–7) | 5 (2–9) | 0.32 |
| No. of measurements in therapeutic range | Median (IQR) | 1 (0–2) | 2 (1–5) | 1 (0–3) | |
a
VA, venoarterial; VV, venovenous; SD, standard deviation; APACHE III, acute physiology and chronic evaluation III; IQR, interquartile range.